1. Home
  2. SRDX vs DCTH Comparison

SRDX vs DCTH Comparison

Compare SRDX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRDX
  • DCTH
  • Stock Information
  • Founded
  • SRDX 1979
  • DCTH 1988
  • Country
  • SRDX United States
  • DCTH United States
  • Employees
  • SRDX N/A
  • DCTH 76
  • Industry
  • SRDX Medical/Dental Instruments
  • DCTH Medical/Dental Instruments
  • Sector
  • SRDX Health Care
  • DCTH Health Care
  • Exchange
  • SRDX Nasdaq
  • DCTH Nasdaq
  • Market Cap
  • SRDX 415.4M
  • DCTH 426.3M
  • IPO Year
  • SRDX 1998
  • DCTH N/A
  • Fundamental
  • Price
  • SRDX $30.91
  • DCTH $11.52
  • Analyst Decision
  • SRDX Buy
  • DCTH Strong Buy
  • Analyst Count
  • SRDX 2
  • DCTH 4
  • Target Price
  • SRDX $43.00
  • DCTH $24.00
  • AVG Volume (30 Days)
  • SRDX 92.6K
  • DCTH 873.0K
  • Earning Date
  • SRDX 07-30-2025
  • DCTH 08-04-2025
  • Dividend Yield
  • SRDX N/A
  • DCTH N/A
  • EPS Growth
  • SRDX N/A
  • DCTH N/A
  • EPS
  • SRDX N/A
  • DCTH N/A
  • Revenue
  • SRDX $121,575,000.00
  • DCTH $53,850,000.00
  • Revenue This Year
  • SRDX N/A
  • DCTH $155.42
  • Revenue Next Year
  • SRDX $3.70
  • DCTH $37.93
  • P/E Ratio
  • SRDX N/A
  • DCTH N/A
  • Revenue Growth
  • SRDX N/A
  • DCTH 1068.87
  • 52 Week Low
  • SRDX $26.00
  • DCTH $7.17
  • 52 Week High
  • SRDX $42.25
  • DCTH $18.23
  • Technical
  • Relative Strength Index (RSI)
  • SRDX 65.27
  • DCTH 32.83
  • Support Level
  • SRDX $29.51
  • DCTH $12.11
  • Resistance Level
  • SRDX $31.06
  • DCTH $14.15
  • Average True Range (ATR)
  • SRDX 0.91
  • DCTH 0.57
  • MACD
  • SRDX 0.18
  • DCTH -0.16
  • Stochastic Oscillator
  • SRDX 86.61
  • DCTH 9.67

About SRDX Surmodics Inc.

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: